Galmed Pharmaceuticals
GLMD
10 hedge funds and large institutions have $6.52M invested in Galmed Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
45% more capital invested
Capital invested by funds: $4.49M → $6.52M (+$2.02M)
25% more funds holding
Funds holding: 8 → 10 (+2)
0.01% more ownership
Funds ownership: 0.04% → 0.05% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GL
GLG LLC
New York
|
+$477K |
| 2 |
Morgan Stanley
New York
|
+$208K |
| 3 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$96.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$40.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$942 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$100K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$24K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
6CM
1
683 Capital Management
New York
| $3.1M | – | – | – |
|
|
PWAM
2
Park West Asset Management
San Francisco,
California
| $1.27M | – | – | – |
|
|
PAWC
3
P.A.W. Capital
Greenwich,
Connecticut
| $744K | – | – | – |
|
|
4
Morgan Stanley
New York
| $596K | +$208K | +221 | +71% |
|
|
GL
5
GLG LLC
New York
| $565K | +$477K | +506 | New |
|
|
SKK
6
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| $114K | +$96.1K | +102 | New |
|
|
CA
7
CapWealth Advisors
Franklin,
Tennessee
| $74K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $48K | +$40.5K | +43 | New |
|
|
RFA
9
Reilly Financial Advisors
La Mesa,
California
| $2K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $1K | +$942 | +1 | New |
|
|
VKH
11
Virtu KCG Holdings
New York
| – | -$100K | -114 | Closed |
|
|
12
Wells Fargo
San Francisco,
California
| – | -$24K | -28 | Closed |
|
GLMD Hedge Fund Activity: Q2 2017 in Review
10 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2017, worth a combined $6.52M — up 45% from $4.49M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GLMD positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was GLG LLC, opening a new position worth an estimated $477K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $100K sold.
- 10 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2017, up from 8 in Q1 2017.
- Funds reported $6.52M of Galmed Pharmaceuticals stock for Q2 2017, up 45% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2017 was GLG LLC, an estimated $477K added.
- The largest Galmed Pharmaceuticals seller in Q2 2017 was Virtu KCG Holdings, an estimated $100K sold.
Based on aggregated 13F filings for Q2 2017.